Continuous subcutaneous hydrocortisone infusion viable option to normalize cortisol
Continuous subcutaneous hydrocortisone infusion was a safe approach for decreasing adrenocorticotropic hormone and cortisol levels to a normal circadian level with minimal adverse effects on glucocorticoid metabolism compared with conventional oral hydrocortisone replacement therapy, according to results in a prospective crossover study.
These data suggest a physiological glucocorticoid replacement therapy may be beneficial and that the infusion may become an option for patients with poorly controlled levels such as those with Addison’s disease, according to Marianne Øksnes, MD, of the department of clinical science and department of medicine at the University of Bergen in Norway, and colleagues.
Patients with Addison’s disease (n=33) were assessed at baseline and after 8 and 12 weeks in each treatment arm, according to data.
The infusion allowed the normalization of adrenocorticotropic hormone (ACTH) and cortisol levels, and 24-hour salivary cortisol curves appeared to reach normal circadian variation, the researchers wrote.
“This study shows that [continuous subcutaneous hydrocortisone infusion] can safely re-establish the circadian cortisol rhythm and normalize morning ACTH levels in [Addison’s disease] patients, which is in sharp contrast to the typical daytime cortisol peaks and troughs and elevated morning ACTH seen with [oral hydrocortisone] treatment,” researchers wrote.
The oral hydrocortisone yielded major alterations in glucocorticoid metabolites and metabolic enzyme activities, according to researchers. However, the infusion appeared to restore glucocorticoid metabolism close to normal.
No significant between-treatment differences were observed in sleep outcomes, according to data.
Additional studies are warranted to determine further ultradian rhythm improvement outcomes for patients with Addison’s disease.
Disclosure: The researchers report no relevant financial disclosures.